Novo Nordisk: Oddo remains neutral after 'mixed' Q4
(CercleFinance.com) - On Wednesday an analyst at Oddo BHF confirmed his "neutral" rating on the Novo Nordisk share, after having noted a mixed Q4, and a cautious guidance for its 2020 margin.
The market should focus on the guidance for 2020, which it believes is cautious: the group forecasts sales growth of between +3% and +6%, while EBIT growth is expected between 1% and 5% at constant currencies, with a positive currency impact of +1%. The broker foresees that estimates will be reduced by 1.5% to 2%.
The analyst therefore confirms a target price of 366 Danish kronor, meanings downside potential of 12%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.